COVID-19
COVID-19
Coronaviruses are enveloped RNA viruses causing respiratory and digestive tract diseases in humans and animals. The SARS-CoV-2 virus, responsible for COVID-19, is primarily transmitted through close contact with infected individuals. The virus can be detected in various bodily fluids and samples, with symptoms appearing 1-3 days post-infection. Immunity to COVID-19 is not yet established, with a reported mortality rate of 2-3%.
Diagnosis relies on clinical symptoms, epidemiological history, and laboratory tests. Serological tests, which detect antibodies, are supportive and should be confirmed by direct virus detection. Antibody levels typically rise in the second week after symptom onset, with IgA and IgM detectable from days 3-6 and IgG from days 10-18.
The ELISA and Microblot-Array kits use a sandwich ELISA method to detect IgA, IgG, and IgM antibodies. The process involves sample dilution, incubation, washing, and colorimetric detection at 450 nm.
These kits are used for disease diagnostics, prevalence studies, and post-vaccination antibody detection. They offer high specificity and sensitivity, reproducibility, and are ready for automation.
ELISA kits show high diagnostic sensitivity and specificity across different antibody types (IgA, IgG, IgM) for both NP and RBD antigens. Microblot-Array kits also demonstrate high sensitivity and specificity, with detailed prevalence data provided for different stages of infection.
The kits offer ready-to-use components, color-coded and interchangeable parts, and are suitable for automated processing. They provide semiquantitative and quantitative evaluation of results, with high diagnostic accuracy.
ELISA and Microblot-Array kits are available for various antibody types, with specific catalog numbers for ordering. The company is certified to ISO 9001 and ISO 13485 standards for in vitro diagnostics.
Catalog excerpts
INFECTIOUS SEROLOGY – VIROLOGY – COVID-19 ELISA and Microblot-Array kits are optimized and validated for detection of IgA, IgG and IgM antibodies in human serum or plasma Diagnostic kits are intended for professional use in the laboratory. Enzyme immunoassays for the diagnostics of infection caused by SARS-CoV-2 virus (COVID-19
Open the catalog to page 1
INFECTIOUS SEROLOGY – VIROLOGY – COVID-19 Coronaviruses, which were discovered in the 1960s, be- The diagnostics of the disease is based on the clinical long to the family of enveloped RNA viruses. They fall picture, epidemiological history, and laboratory tests. in the group of zoonotic infections that cause disea- Due to the several-day-long interval between the first ses of the respiratory and digestive tracts in humans and animals (birds, mammals). Coronaviruses cause diverse clinical pictures, from common cold to severe respiratory syndromes (MERS, SARS and COVID-19). The majority of known...
Open the catalog to page 2
Antibody post-infection response Contact with virus Infection stage Presumed immunity time / days
Open the catalog to page 3
INFECTIOUS SEROLOGY - VIROLOGY - COVID-19 Test Principle The assays are based on a sandwich type of ELISA EIA COVID-19 NP method. Nucleocapsid recombinant antigen (NP) Sandwich ELISA ^HRP^ ^HRp) EIA COVID-19 RBD Recombinant Receptor-binding domain (RBD) antigen and combination of S1 Spike relevant SARS-CoV-2 mutations Microtiter plate Clinical Application - Diagnostics of the disease (additional examination) - Prevalence study - Detection of post-vaccination antibodies (RBD) Summary Protocol User C°mf°rt Step Test steps - serum/plasma 1:101 (10 pl + 1 ml) 2. Pipette Controls and diluted samples...
Open the catalog to page 4
Types of Kits SmartEIA kits are designed for automated processing using the Agility® analyser.
Open the catalog to page 5
INFECTIOUS SEROLOGY – VIROLOGY – COVID-19 Overview of post-vaccination reactivity of ELISA kits 12 11 10 9 Index positivity 40 individuals were tested after the 1st dose, 2nd of the vaccine (Pfizer/BioNTech) and then after 3 months and 6 months after the vaccination was completed. Values in the graph are the arythmetic mean of obtained values. Correlation of VNT and ELISA kit results Mean Index of Positivity (IP) values of IgG anti-RBD antibodies (TestLine) in relation to individual VNT titers 1000
Open the catalog to page 6
Distribution of antigens A1 - Nucleocapsid NP A2 -RBD A3 - Spike S1 A4 - Spike S2 A5 - Spike S1 a-variant (UK) A6 - Spike S1 Y-variant (Brazil) A7 - Spike S1 8-variant (Indian) A8 - Envelope protein (E) A9 -ACE2 A10 - PLPro protein A11 - MERS-CoV A12 - SARS-CoV A13 - HCoV 229E Np A14 - HCoV NL63 Np Distribution of control spots (r) O R - Reference O TC - Test control O CG - Conjugate control IgG O CM - Conjugate control IgM O C1 - Calibration 1 O C2 - Calibration 2 O C3 - Calibration 3 O C4 - Calibration 4 Overview of specific antigens Antigens Description Receptor binding domain S1 RBD subunit...
Open the catalog to page 7
INFECTIOUS SEROLOGY – VIROLOGY – COVID-19 Summary Protocol Step Pipette Universal solution 150 μl Strips soaking 10 min. at room temperature Incubate 30 min. at room temperature Advantages Efficiency – Analysis of up to 96 patient samples per plate – Low sample consumption – Parallel testing of multiple markers simultaneously Automation – Possibility of automated processing using an ELISA instrument Dilute samples – serum/plasma 1:51 (10 μl + 500 μl) Pipette Controls and diluted samples – Intuitive software for test evaluation – Remote troubleshooting – LIS connectivity 100 μl Incubate 30 min....
Open the catalog to page 8
MBA COVID-19 IgA (n=207) Days from initial symptoms
Open the catalog to page 9
INFECTIOUS SEROLOGY - VIROLOGY - COVID-19 potential endemic cross-reactivities coronaviruses
Open the catalog to page 10
Overview of post-vaccination reactivity of Microblot-Array kits Mean values after the 1st dose of vaccination Mean values after the 2nd dose of vaccination Correlation of VNT and Microblot-Array kit results VNT vs MBA TL IgG Mean values of units per millilitre IgG anti-RBD antibodies and IgG anti-NP antibodies (TestLine) in relation to individual VNT titers Mean values of units per millilitre IgG anti-RBD Mean values of units per millilitre IgG anti-NP antibodies (TestLine) in relation to individual antibodies (TestLine) in relation to individual
Open the catalog to page 11
INFECTIOUS SEROLOGY – VIROLOGY – COVID-19 Ordering information ELISA Cat. No. SmartEIA kits are designed for automated processing using the Agility® analyser. MICROBLOT-ARRAY Product TestLine Clinical Diagnostics Ltd. Krizikova 68, 612 00 Brno, Czech Republic +420 549 121 203 management system standards Company is certified to the quality
Open the catalog to page 12All TestLine Clinical Diagnostics catalogs and technical brochures
Herpes Simplex Virus8 Pages
Cytomegalovirus8 Pages
Parvovirus B194 Pages
Veterinary Portfolio20 Pages
Respiratory viruses8 Pages
- Detection kit
- Solvent reagent
- Blood detection kit
- Serum detection kit
- Immunoassay detection kit
- Plasma detection kit
- Analysis software
- Infectious disease detection kit
- Diagnostic reagent
- Respiratory disease assay kit
- Medium reagent
- COVID-19 assay kit
- Laboratory software
- Bacteria reagent
- Clinical reagent
- Test strip
- Animal detection kit
- IgG assay kit